From standard therapies to monoclonal antibodies and immune checkpoint inhibitors – an update for reconstructive surgeons on common oncological cases
Malignancies represent a persisting worldwide health burden. Tumor treatment is commonly based on surgical and/or non-surgical therapies. In the recent decade, novel non-surgical treatment strategies involving monoclonal antibodies (mAB) and immune checkpoint inhibitors (ICI) have been successfully...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-04-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1276306/full |
| _version_ | 1797196028923871232 |
|---|---|
| author | Leonard Knoedler Leonard Knoedler Lioba Huelsboemer Katharina Hollmann Katharina Hollmann Michael Alfertshofer Konstantin Herfeld Konstantin Herfeld Helia Hosseini Sam Boroumand Viola A. Stoegner Viola A. Stoegner Ali-Farid Safi Ali-Farid Safi Markus Perl Markus Perl Samuel Knoedler Samuel Knoedler Bohdan Pomahac Martin Kauke-Navarro |
| author_facet | Leonard Knoedler Leonard Knoedler Lioba Huelsboemer Katharina Hollmann Katharina Hollmann Michael Alfertshofer Konstantin Herfeld Konstantin Herfeld Helia Hosseini Sam Boroumand Viola A. Stoegner Viola A. Stoegner Ali-Farid Safi Ali-Farid Safi Markus Perl Markus Perl Samuel Knoedler Samuel Knoedler Bohdan Pomahac Martin Kauke-Navarro |
| author_sort | Leonard Knoedler |
| collection | DOAJ |
| description | Malignancies represent a persisting worldwide health burden. Tumor treatment is commonly based on surgical and/or non-surgical therapies. In the recent decade, novel non-surgical treatment strategies involving monoclonal antibodies (mAB) and immune checkpoint inhibitors (ICI) have been successfully incorporated into standard treatment algorithms. Such emerging therapy concepts have demonstrated improved complete remission rates and prolonged progression-free survival compared to conventional chemotherapies. However, the in-toto surgical tumor resection followed by reconstructive surgery oftentimes remains the only curative therapy. Breast cancer (BC), skin cancer (SC), head and neck cancer (HNC), and sarcoma amongst other cancer entities commonly require reconstructive surgery to restore form, aesthetics, and functionality. Understanding the basic principles, strengths, and limitations of mAB and ICI as (neo-) adjuvant therapies and treatment alternatives for resectable or unresectable tumors is paramount for optimized surgical therapy planning. Yet, there is a scarcity of studies that condense the current body of literature on mAB and ICI for BC, SC, HNC, and sarcoma. This knowledge gap may result in suboptimal treatment planning, ultimately impairing patient outcomes. Herein, we aim to summarize the current translational endeavors focusing on mAB and ICI. This line of research may serve as an evidence-based fundament to guide targeted therapy and optimize interdisciplinary anti-cancer strategies. |
| first_indexed | 2024-04-24T06:21:34Z |
| format | Article |
| id | doaj.art-7318d3bbb6eb4b1d84d3ea5542bc12af |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-24T06:21:34Z |
| publishDate | 2024-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-7318d3bbb6eb4b1d84d3ea5542bc12af2024-04-23T04:49:51ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-04-011510.3389/fimmu.2024.12763061276306From standard therapies to monoclonal antibodies and immune checkpoint inhibitors – an update for reconstructive surgeons on common oncological casesLeonard Knoedler0Leonard Knoedler1Lioba Huelsboemer2Katharina Hollmann3Katharina Hollmann4Michael Alfertshofer5Konstantin Herfeld6Konstantin Herfeld7Helia Hosseini8Sam Boroumand9Viola A. Stoegner10Viola A. Stoegner11Ali-Farid Safi12Ali-Farid Safi13Markus Perl14Markus Perl15Samuel Knoedler16Samuel Knoedler17Bohdan Pomahac18Martin Kauke-Navarro19Department of Plastic, Hand, and Reconstructive Surgery, University Hospital Regensburg, Regensburg, GermanyDivision of Plastic Surgery, Department of Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, CT, United StatesDivision of Plastic Surgery, Department of Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, CT, United StatesDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United StatesFaculty of Medicine, University of Wuerzbuerg, Wuerzburg, GermanyDivision of Hand, Plastic and Aesthetic Surgery, Ludwig-Maximilians University Munich, Munich, GermanyDepartment of Internal Medicine III (Oncology and Haematology), University Hospital Regensburg, Regensburg, GermanyLeibniz Institute for Immunotherapy, Regensburg, GermanyDivision of Plastic Surgery, Department of Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, CT, United StatesDivision of Plastic Surgery, Department of Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, CT, United StatesDivision of Plastic Surgery, Department of Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, CT, United StatesDepartment of Plastic, Aesthetic, Hand and Reconstructive Surgery, Burn Center, Hannover Medical School, Hannover, GermanyCraniologicum, Center for Cranio-Maxillo-Facial Surgery, Bern, Switzerland0Faculty of Medicine, University of Bern, Bern, SwitzerlandDepartment of Internal Medicine III (Oncology and Haematology), University Hospital Regensburg, Regensburg, GermanyLeibniz Institute for Immunotherapy, Regensburg, GermanyDepartment of Plastic, Hand, and Reconstructive Surgery, University Hospital Regensburg, Regensburg, GermanyDivision of Plastic Surgery, Department of Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, CT, United StatesDivision of Plastic Surgery, Department of Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, CT, United StatesDivision of Plastic Surgery, Department of Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, CT, United StatesMalignancies represent a persisting worldwide health burden. Tumor treatment is commonly based on surgical and/or non-surgical therapies. In the recent decade, novel non-surgical treatment strategies involving monoclonal antibodies (mAB) and immune checkpoint inhibitors (ICI) have been successfully incorporated into standard treatment algorithms. Such emerging therapy concepts have demonstrated improved complete remission rates and prolonged progression-free survival compared to conventional chemotherapies. However, the in-toto surgical tumor resection followed by reconstructive surgery oftentimes remains the only curative therapy. Breast cancer (BC), skin cancer (SC), head and neck cancer (HNC), and sarcoma amongst other cancer entities commonly require reconstructive surgery to restore form, aesthetics, and functionality. Understanding the basic principles, strengths, and limitations of mAB and ICI as (neo-) adjuvant therapies and treatment alternatives for resectable or unresectable tumors is paramount for optimized surgical therapy planning. Yet, there is a scarcity of studies that condense the current body of literature on mAB and ICI for BC, SC, HNC, and sarcoma. This knowledge gap may result in suboptimal treatment planning, ultimately impairing patient outcomes. Herein, we aim to summarize the current translational endeavors focusing on mAB and ICI. This line of research may serve as an evidence-based fundament to guide targeted therapy and optimize interdisciplinary anti-cancer strategies.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1276306/fullbreast cancersarcomahead and neck cancerskin cancermalignant melanomamonoclonal antibody |
| spellingShingle | Leonard Knoedler Leonard Knoedler Lioba Huelsboemer Katharina Hollmann Katharina Hollmann Michael Alfertshofer Konstantin Herfeld Konstantin Herfeld Helia Hosseini Sam Boroumand Viola A. Stoegner Viola A. Stoegner Ali-Farid Safi Ali-Farid Safi Markus Perl Markus Perl Samuel Knoedler Samuel Knoedler Bohdan Pomahac Martin Kauke-Navarro From standard therapies to monoclonal antibodies and immune checkpoint inhibitors – an update for reconstructive surgeons on common oncological cases Frontiers in Immunology breast cancer sarcoma head and neck cancer skin cancer malignant melanoma monoclonal antibody |
| title | From standard therapies to monoclonal antibodies and immune checkpoint inhibitors – an update for reconstructive surgeons on common oncological cases |
| title_full | From standard therapies to monoclonal antibodies and immune checkpoint inhibitors – an update for reconstructive surgeons on common oncological cases |
| title_fullStr | From standard therapies to monoclonal antibodies and immune checkpoint inhibitors – an update for reconstructive surgeons on common oncological cases |
| title_full_unstemmed | From standard therapies to monoclonal antibodies and immune checkpoint inhibitors – an update for reconstructive surgeons on common oncological cases |
| title_short | From standard therapies to monoclonal antibodies and immune checkpoint inhibitors – an update for reconstructive surgeons on common oncological cases |
| title_sort | from standard therapies to monoclonal antibodies and immune checkpoint inhibitors an update for reconstructive surgeons on common oncological cases |
| topic | breast cancer sarcoma head and neck cancer skin cancer malignant melanoma monoclonal antibody |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1276306/full |
| work_keys_str_mv | AT leonardknoedler fromstandardtherapiestomonoclonalantibodiesandimmunecheckpointinhibitorsanupdateforreconstructivesurgeonsoncommononcologicalcases AT leonardknoedler fromstandardtherapiestomonoclonalantibodiesandimmunecheckpointinhibitorsanupdateforreconstructivesurgeonsoncommononcologicalcases AT liobahuelsboemer fromstandardtherapiestomonoclonalantibodiesandimmunecheckpointinhibitorsanupdateforreconstructivesurgeonsoncommononcologicalcases AT katharinahollmann fromstandardtherapiestomonoclonalantibodiesandimmunecheckpointinhibitorsanupdateforreconstructivesurgeonsoncommononcologicalcases AT katharinahollmann fromstandardtherapiestomonoclonalantibodiesandimmunecheckpointinhibitorsanupdateforreconstructivesurgeonsoncommononcologicalcases AT michaelalfertshofer fromstandardtherapiestomonoclonalantibodiesandimmunecheckpointinhibitorsanupdateforreconstructivesurgeonsoncommononcologicalcases AT konstantinherfeld fromstandardtherapiestomonoclonalantibodiesandimmunecheckpointinhibitorsanupdateforreconstructivesurgeonsoncommononcologicalcases AT konstantinherfeld fromstandardtherapiestomonoclonalantibodiesandimmunecheckpointinhibitorsanupdateforreconstructivesurgeonsoncommononcologicalcases AT heliahosseini fromstandardtherapiestomonoclonalantibodiesandimmunecheckpointinhibitorsanupdateforreconstructivesurgeonsoncommononcologicalcases AT samboroumand fromstandardtherapiestomonoclonalantibodiesandimmunecheckpointinhibitorsanupdateforreconstructivesurgeonsoncommononcologicalcases AT violaastoegner fromstandardtherapiestomonoclonalantibodiesandimmunecheckpointinhibitorsanupdateforreconstructivesurgeonsoncommononcologicalcases AT violaastoegner fromstandardtherapiestomonoclonalantibodiesandimmunecheckpointinhibitorsanupdateforreconstructivesurgeonsoncommononcologicalcases AT alifaridsafi fromstandardtherapiestomonoclonalantibodiesandimmunecheckpointinhibitorsanupdateforreconstructivesurgeonsoncommononcologicalcases AT alifaridsafi fromstandardtherapiestomonoclonalantibodiesandimmunecheckpointinhibitorsanupdateforreconstructivesurgeonsoncommononcologicalcases AT markusperl fromstandardtherapiestomonoclonalantibodiesandimmunecheckpointinhibitorsanupdateforreconstructivesurgeonsoncommononcologicalcases AT markusperl fromstandardtherapiestomonoclonalantibodiesandimmunecheckpointinhibitorsanupdateforreconstructivesurgeonsoncommononcologicalcases AT samuelknoedler fromstandardtherapiestomonoclonalantibodiesandimmunecheckpointinhibitorsanupdateforreconstructivesurgeonsoncommononcologicalcases AT samuelknoedler fromstandardtherapiestomonoclonalantibodiesandimmunecheckpointinhibitorsanupdateforreconstructivesurgeonsoncommononcologicalcases AT bohdanpomahac fromstandardtherapiestomonoclonalantibodiesandimmunecheckpointinhibitorsanupdateforreconstructivesurgeonsoncommononcologicalcases AT martinkaukenavarro fromstandardtherapiestomonoclonalantibodiesandimmunecheckpointinhibitorsanupdateforreconstructivesurgeonsoncommononcologicalcases |